Skip to main content
. Author manuscript; available in PMC: 2011 Aug 9.
Published in final edited form as: J Neurooncol. 2010 Nov 30;104(1):83–92. doi: 10.1007/s11060-010-0473-5

Figure 3. Treatment with anti-CCL2 mAb modestly prolongs the survival of glioma-bearing mice.

Figure 3

C57BL/6 mice bearing GL261 glioma (a) or SCID mice bearing human U87 glioma (b) were treated with anti-mouse CCL2 mAb or both anti-mouse CCL2 mAb and anti-human CCL2 mAb, respectively, by i.p. injections starting on day 7, twice weekly up to 8 weeks after tumor cell inoculation (2 mg/kg/dose for each mAb). Mice in control groups received corresponding control IgG. Symptom-free survival (SFS) of mice was monitored (for GL261 model, n=5 and 11 for control and anti-CCL2 mAb group respectively; for U87 model, n=10/group.). **p = 0.0033 for SFS of C57BL/6 mice with anti-mouse CCL2 mAb vs. that with control IgG; *p = 0.0159 for SFS of SCID mice treated with both anti-mouse and anti-human CCL2 mAbs vs. that with control IgGs. α-mCCL2 refers to anti-mouse CCL2 antibody; α-hCCL2 refers to anti-human CCL2 antibody.